auph FDA approval retrace

NASDAQ:AUPH   Aurinia Pharmaceuticals Inc
Spike from FDA approval. Anticipate pull back to 61 fib level. MT - price target is 61 feb extension level.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.